BioCentury | Jan 25, 2016
Clinical News

VTP-34072: Additional Phase II data

Top-line data from the monotherapy arm of the double-blind, German Phase II trial in overweight Type II diabetics showed that once-daily oral VTP-34072 missed the “predefined primary efficacy endpoint criteria” of the change in FPG...
BioCentury | Jul 13, 2015
Analyst Picks & Changes

Analyst picks & changes

Analyst picks & changes Analyst picks & changes Company Bank Analyst Coverage Opinion Wk chg 7/10 cls Amgen Inc. (NASDAQ:AMGN) UBS Matthew Roden Downgrade Neutral (from buy) 1% $154.10 Roden also lowered his target to...
BioCentury | Jul 13, 2015
Clinical News

VTP-34072: Phase II data

Top-line data from a double-blind, German Phase II trial in overweight Type II diabetics showed that once-daily oral VTP-34072 as an add-on to metformin background therapy missed Boehringer’s “predefined endpoint criteria” on the primary efficacy...
Items per page:
1 - 3 of 3